Sermorelin Acetate Injection Recalled Due to Sterility Assurance Issues
Sermorelin Acetate injectable (76 vials) recalled nationwide due to manufacturing deviations that compromise sterility assurance. No illnesses reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a sterile injectable product with manufacturing deviations that call sterility into question. This is a risk-of-harm product where no illnesses or injuries have been reported, placing it at the High severity level per the rubric.
Plain-English summary
North American Custom Laboratories, LLC (dba FarmaKeio Superior Custom Compounding) is recalling Sermorelin Acetate 1 mg/mL injection in 6 mL vials due to a lack of assurance of sterility. The recall affects 76 vials with lot numbers 32963 (BUD 4/12/2022), 34824 (BUD 5/30/2022), and 35130 (BUD 6/7/2022). This prescription injectable was distributed nationwide.
The FDA determined that deviations from Current Good Manufacturing Practices (CGMP) call into question whether the product meets sterility requirements. Because this is a sterile injectable medication intended for direct administration to patients, any compromise in sterility assurance poses a potential infection risk.
Patients who have received this product should contact their healthcare provider or pharmacist immediately. The medication should not be used and should be returned to the pharmacy or disposed of according to local pharmaceutical waste guidelines.
The recalled product
- Product
- Sermorelin Acetate 1 mg/mL (6 mL) Injection, 6 mL vials, Rx only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081
- Manufacturer
- North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding
- Category
- Drug — Injectable / Prescription
- Hazard
- sterility-assurance
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: 32963 BUD: 4/12/2022
- 34824 BUD: 5/30/2022
- 35130 BUD: 6/7/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27